Abstract
BackgroundAIDAI is a novel validated tool for assessment of disease activity in autoinflammatory diseases.1 CLUSTER study (NCT02059291) demonstrated that canakinumab (CAN; an anti- IL-1β antibody) is efficacious in resolving active...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have